Your browser doesn't support javascript.
loading
Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Adverse Drug-Induced Inotropic Effects in Early Drug Development. Part 1: General Considerations for Development of Novel Testing Platforms.
Guth, Brian D; Engwall, Michael; Eldridge, Sandy; Foley, C Michael; Guo, Liang; Gintant, Gary; Koerner, John; Parish, Stanley T; Pierson, Jennifer B; Ribeiro, Alexandre J S; Zabka, Tanja; Chaudhary, Khuram W; Kanda, Yasunari; Berridge, Brian.
Afiliação
  • Guth BD; Department of Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riss, Germany.
  • Engwall M; PreClinical Drug Development Platform (PCDDP), North-West University, Potchefstroom, South Africa.
  • Eldridge S; Safety Pharmacology and Animal Research Center, Amgen Research, Thousand Oaks, CA, United States.
  • Foley CM; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
  • Guo L; Department of Integrative Pharmacology, Integrated Sciences and Technology, AbbVie, North Chicago, IL, United States.
  • Gintant G; Laboratory of Investigative Toxicology, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, United States.
  • Koerner J; Department of Integrative Pharmacology, Integrated Sciences and Technology, AbbVie, North Chicago, IL, United States.
  • Parish ST; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, United States.
  • Pierson JB; Health and Environmental Sciences Institute, Washington, DC, United States.
  • Ribeiro AJS; Health and Environmental Sciences Institute, Washington, DC, United States.
  • Zabka T; Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translation Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, United States.
  • Chaudhary KW; Department of Safety Assessment, Genentech, South San Francisco, CA, United States.
  • Kanda Y; Global Safety Pharmacology, GlaxoSmithKline plc, Collegeville, PA, United States.
  • Berridge B; Division of Pharmacology, National Institute of Health Sciences, Kanagawa, Japan.
Front Pharmacol ; 10: 884, 2019.
Article em En | MEDLINE | ID: mdl-31447679
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies Idioma: En Revista: Front Pharmacol Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Alemanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies Idioma: En Revista: Front Pharmacol Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Alemanha